Lara Sullivan

CIK: 0001769457

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PYXS

Pyxis Oncology, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
918.3K shares at avg. $0.98-
PYXS
Pyxis Oncology, Inc.
Dec 23, 2024
Award(A)
Stock Option (Right to Buy)
Direct
1.1M shares-

		Type	Shares	Price		Ownership
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	918,308	$0.98	-	Direct
Dec 23, 2024	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	1,135,000	-	-	Direct

1-2 of 2 transactions

About Sullivan Lara

Sullivan Lara (SEC CIK 0001769457) files insider reports with the SEC as Chief Executive Officer of Pyxis Oncology, Inc. (PYXS).

Signal8 holds 2 ownership filings by Sullivan Lara, all Form 4s, filed between Dec 23, 2024 and Apr 2, 2025. Those filings report 2 transactions, from Dec 23, 2024 to Mar 31, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Sullivan Lara's filings is in BOSTON, MA.

Recent filings by Sullivan Lara

Mar 31, 2025: Grant or award of PYXS derivative securities (Form 4, code A).
Dec 23, 2024: Grant or award of PYXS derivative securities (Form 4, code A).

Other insiders filing for Pyxis Oncology, Inc. (PYXS)

GordonMD Global Investments LP, 10% Owner
Civik Thomas, CEO & Chairman of the Board
Dupont Jakob, Director
Wadhane Jitendra, Prin Fin & Acct Officer
FLAVIN JOHN L, Director
Metzger Michael A, Director

How to read Form 4 transaction codes